The Busiest Dealmakers Of 2022
NewS Archive
GeekWire
Seattle biotech startup born out of a Roche buyout lands $93M to advance therapies
BioPharmaDive
After $250M Roche buyout, a startup plans a second strike with fresh funding
Genetic Engineering & Biotechnology News
From Good to Great: Bonum Therapeutics Raises $93M Series A with Allosterically Regulated Medicines
Endpoints News
The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs
Fierce Biotech
Roche-backed Bonum bags $93M series A to develop new class of conditionally active therapies
BioSpace
Good Therapeutics’ Offshoot Bonum Launches with $93 Million in Series A (Updated)